Clinical pharmacokinetics of nisoldipine coat-core

Clinical Pharmacokinetics

Volumn 35, Issue 3, 1998, Pages 191-208

  Heinig, Roland ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CIMETIDINE; CYTOCHROME P450; DIGITALIS GLYCOSIDE; NISOLDIPINE; PHENYTOIN; PROPRANOLOL; QUINIDINE; RANITIDINE; RIFAMPICIN;

AGE; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; FOOD INTAKE; FRUIT JUICE; GASTROINTESTINAL ABSORPTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIPID DIET; LIVER CIRRHOSIS; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; STEREOCHEMISTRY;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; ETHNIC GROUPS; FOOD-DRUG INTERACTIONS; HUMANS; HYPERTENSION; KIDNEY DISEASES; LIVER DISEASES; NISOLDIPINE; STEREOISOMERISM;

EID: 0031709133     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835030-00003     Document Type: Article

References (75)

1. Scherling D, Ahr G, Karl W. Biotransformation of nisoldipine in man. In: Hugenholtz PG, Meyer J, editors. Nisoldipine 1987. Berlin: Springer, 1987: 85-8
2. Seedal YK. The long-term efficacy and tolerability of nisoldipine in patients with mild-to-moderate hypertension. Ther Res 1997; 58 (3): 187-99
3. Nisoldipine: a new calcium channel blocker for hypertension [editorial]. Med Lett Drug Ther 1996 Feb 16; 38 (968): 13-4
4. Plosker GL, Faulds D. Nisoldipine coat-core: a review of its pharmacology and therapeutic efficacy in hypertension. Drugs 1996 Aug; 52 (2): 232-53
5. Van Harten J, Lodewijks MThM, Guyt-Scholten JW, et al. Gas chromatographic determination of nisoldipine and one of its metabolites in plasma. J Chromatogr 1987; 423: 327-33
6. Ahr G, Wingender W, Kuhlmann J. Pharmacokinetics of nisoldipine. In: Hugenholtz PG, Meyer J, editors. Nisoldipine 1987. Berlin: Springer, 1987: 59-66
7. Ottosson AM, Anderson P, Bondesson U, et al. Analysis and pharmacokinetics of nisoldipine in hypertensive patients. Curr Ther Res 1989 45 (3): 347-58
8. Frost N, Ahr G, Weber, H, et al. Nisoldipine enantiomers-assessment of pharmaco-kinetics by stable isotope technique. In: Kuhlmann J, Wingender W, editors. Dose-response relationship of drugs. Munich: W. Zuckschwerdt, 1990: 87-92
9. Heinig R, Muschalek V, Ahr G. Determination of the enantiomers of nisoldipine in human plasma using high-performance liquid chromatography on a chiral stationary phase and gas chromatography with mass-selective detection. J Chromatogr 1994; 655: 286-92
10. Likussar W, Reiner J, Michelitsch A, et al. Redoxeigenschaften und photochemisches Verhalten von Nisoldipin [abstract]. Sci Pharm 1991; 59: 37
11. Michelitsch A, Reiner J, Schubert-Zsilavecz M, et al. 2,2′-Bis(3-isobutyloxy- carbonyl-5-methoxycarbonyl-2,6-dimethyl-4-pyridyl)-azobenzene-N,N′- dioxide: a new degradation product of nisoldipine by UV light. Pharmazie 1995; 50 (8): 548-9
12. Scherling D, Karl W, Ahr G, et al. Pharmacokinetics of nisoldipine: III. Biotransformation of nisoldipine in rat, dog, monkey, and man. Arzneimittel Forschung 1988; 38 (8): 1105-10
13. Van Harten J, van Brummelen P, Lodewijks MThM, et al. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther 1988; 43: 332-41
14. Pharmakokinetische und pharmakodynamische Daten von Nisoldipin [editorial]. Fortschr Med 1987; 105 Suppl. 30: 7-9
15. Staib AH, Fuhr U. Drug absorption differences along the gastrointestinal tract in man: detection and relevance for the development of new drug formulations. In: Kuhlmann J, Weihrauch TR, editors. Food-drug interactions. Munich: W. Zuckschwerdt, 1995: 34-56
16. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450IIIA4. J Med Chem 1991; 34: 1838-44
17. Ahr HJ, Ahr G, Pleiss U, et al. Gut wall metabolism of nisoldipine: evidence for a relevant contribution to first pass effect in dogs [abstract]. 12th European Workshop on Drug Metabolism: 1990 Sep 16-21: Basel. 4.1
18. Ahr G, Staib H, Kuhlmann J. Evidence for differences in gut wall metabolism of nisoldipine depending on absorption site [abstract]. Symposium on Recent Progress in Extrahepatic Drug Metabolism; 1991 May 15-17: Ronneby (Sweden): country please). Poster 1
19. van Harten J, van Brummelen P, Wilson JHP, et al. Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration Eur J Clin Pharmacol 1988; 34: 387-94
20. van Harten J, van Brummelen P, Zeegers RRECM, et al. The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. Br J Clin Pharmacol 1988; 25: 709-17
21. van Harten J, Burggraaf J, Danhof M, et al. The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinelics after oral administration. Br J Clin Pharmacol 1989; 27: 581-6
22. Pasanisi F, Meredith PA, Reid JL. The pharmacodynamics and pharmacokinetics of a new calcium-antagonist, nisoldipine, in normotensive and hypertensive subjects. Eur J Clin Pharmacol 1985; 29: 21-4
23. Lasseter KC, Shamblen EC, Lettieri J, et al. Dose-proportional pharmacokinetics of nisoldipine in healthy volunteers [abstract]. Clin Pharmacol Ther 1987; 41 (2): 234
24. Heinig R, Ahr G, Hayauchi Y, et al. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation. Int J Pharmacol Ther 1997 Aug; 35 (8): 341-51
25. Zannad F. Clinical pharmacology of nisoldipine. Am J Cardiol 1995; 75: 41E-5E
26. Chandler MHH, Clifton GD, Lettieri JT, et al. Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. J Clin Pharmacol 1992; 32: 571-5
27. Mazzu AL, Lettieri JT, Krol GJ, et al. Steady-state pharmacokinelics and pharmaco-dynamics of nisoldipine coat-core tablets in hypertensive patients [abstract]. J Clin Pharmacol 1992; 32 (8): 754
28. Schall R, Müller FO, Groenewoud G, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic profiles of nisoldipine coat-core tablets in healthy young, healthy elderly, and elderly hypertensive volunteers. Drug Invest 1994; 8 (1): 21-30
29. Lettieri J, Mazzu A, Shah A, et al. Pharmacokinetic (PK) of nisoldipine and metabolites in renally impaired patients [abstract]. Pharm Res 1993; 10 Suppl. 10: S338
30. Shah A, Krol G, Sundaresan PR. Pharmacokinetics of nisoldipine coal-core formulation in subjects with liver cirrhosis. Am J Therapeutics 1995; 2: 15-9
31. Lasseter KC, Müller FO, Garrett BN, et al. Pharmacokinetics, pharmacodynamics, and clinical utility of nisoldipine coat core in the treatment of essential hypertension. Cardiovasc Rev Rep 1996; 17: 28-38, 44-6
32. Langan L, Rodriguez-Mañas, Sareli P, et al. Nisoldipine CC: clinical experience in hypertension. Cardiology 1997; 88 Suppl. 1: 56-62
33. Bailey DG, Arnold JMO, Strong HA, et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993 Dec; 54 (6): 589-94
34. Schall R, Müller FO, Groenewoud HKL, et al. Investigation of a possible pharmaco-kinetic interaction between nisoldipine and quinidine in healthy volunteers. Drug Invest 1994; 8 (3): 162-70
35. Brendel E, Heinig R, Ahr G, et al. Influence of cimetidine and ranitidine on the pharmacokinetics of controlled-release formulations of the two calcium-antagonists nifedipine and nisoldipine [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1992; 345 Suppl. 1: R3
36. Michelucci G, Cipolla D, Passarelli G, et al. Reduction of nisoldipine bioavailability by induction of first-pass metabolism in phenytoin-treated patients. Epilepsia 1996; 37 (11): 1107-10
37. Adelmann HG, Heinig R, Kuhlmann J. Pharmacodynamic and pharmacokinetic interaction of nisoldipine and propranolol during steady-state conditions [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1991; 344 (1): R89
38. Heinig R, Schäfer HG, Ahr G, et al. Pharmacokinetics and in vitro/in vivo correlation of three different nisoldipine coat core formulations compared to the standard tablet [abstract]. Pharm Res 1991; 8 (10 Suppl.): S300
39. Baksi AK, Edwards JS, Ahr G. A comparison of the pharmacokinetics of nisoldipine in elderly and young subjects. Br J Clin Pharmacol 1991; 31: 367-70
40. van Harten J, Burggraaf J, Ligthart GJ, et al. Single and multiple dose nisoldipine kinetics and effects in the young, middle-aged and the elderly. Clin Pharmacol Ther 1989; 45: 600-7
41. Tanaka T, Terashima S, Yoshikawa K, et al. Investigation on the interethnic differences in the pharmacokinetics of nifedipine and nisoldipine. Jpn J Clin Pharmacol Ther 1996 Mar; 27 (1): 31-2
42. Boelaert J, Valcke Y, Dammekens H, et al. Pharmacokinetics of nisoldipine in renal dysfunction. Eur J Clin Pharmacol 1988; 34: 207-9
43. Van Harten J, Burggraaf J, van Brummelen P, et al. Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing. Clin Pharmacokinet 1989; 16: 55-64
44. Shionoiri H, Minamisawa K, Masumori S, et al. Pharmacokinetics and pharmacodynamics of nisoldipine in hypertensive patients with normal and mild to moderate impaired renal function. Arzneimittel Forschung 1995; 45 (7): 785-9
45. Joeres R, Ahr G, Hofstetter G. Steady-state pharmacokinetics of nisoldipine in patients with liver disease In: Hugenholtz PG, Meyer J, editors. Nisoldipine 1987. Berlin: Springer, 1987: 80-4
46. Blume HH, Schug BS, Potthast H. Influence of food on the bioavailability of controlled/modified release products. In: Kuhlmann J, Weihrauch TR, editors. Food-drug interactions. München: W. Zuckschwerdt, 1995: 25-33
47. Hoon TJ, McCollam PL, Beckman KJ, et al. Impact of food on the pharmacokinetics and electrocardiographic effects of sustained-release verapamil in normal subjects. Am J Cardiol 1992; 70: 1072-6
48. Karim A, Burns T, Wearly L, et al. Food-induced changes in theophylline absorption from controlled-release formulations: I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle. Clin Pharmacol Ther 1985; 38(1): 77-83
49. Fleishacker JC, Phillips JP, Lau HS. Effect of food on the bioavailability of adinazolam from a sustained release formulation. Biopharm Drug Dispos 1990; 11: 715-27
50. Schaefer HG, Heinig R, Ahr G, et al. Pharmacokinetic-pharmacodynamic modeling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharm 1997; 51: 473-80
51. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997 Aug; 33 (2): 103-21
52. Friedel HA, Sorkin EM. Nisoldipine: a preliminary review of its pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1988; 36: 682-731
53. Mück W, Ahr G, Kuhlmann J. Nimodipine: potential for drug-drug interactions in the elderly. Drugs Aging 1995; 6 (3): 229-42
54. Bailey DG, Freeman DJ, Melendez LJ, et al. Quinidine interaction with nifedipine and felodipine: pharmacokinetic and pharmacodynamic evaluation. Clin Pharmacol Ther 1993; 53 (3): 354-9
55. Hippius M, Henschel L, Sigusch H, et al. Pharmacokinetic interaction of nifedipine and quinidine [abstract]. Arch Pharmacol 1994; 349 Suppl.: R138
56. Bowles SK, Reeves RA, Cardozo LJ. Pharmacokinetic-pharmacodynamic interaction between quinidine and nifedi-pine. Pharmacotherapy 1990; 10 (3): 243-4
57. Schellens JH, Ghabrial H, van der Wart HH, et al. Differential effects of quinidine on the disposition of nifedipine, sparteine and mephenytoin in humans. Clin Pharmacol Ther 1991; 50 (5): 520-8
58. Bowles SK, Reeves RA, Cardozo L, et al. Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. J Clin Pharmacol 1993; 33 (8): 727-31
59. Capewell S, Freestone S, Critchley JAJH, et al. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 1988; 11: 480-2
60. Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1991; 32: 335-40
61. Yoshimoto H, Takahashi M, Saima S. Influence of rifampicin on antihypertensive effects of dihydropyridine calcium channel blockers in four elderly patients. Jpn J Geriat 1996; 33: 692-9
62. Mustofa M, Kristin E, Suryawati S, et al. Effects of rifampin pretreatment on the pharmacokinetics of nifedipine in healthy volunteers [abstract]. 5th World Conference of Clinical Pharmacology and Therapeutics; 1992 Jul; Yokohama; P-408-217
63. Shaw-Stiffel TA, Walker SE, Ogilvie RI, et al. Pharmacokinetic and pharmacodynamic interaction during multiple-dose administration of nisoldipine and propranolol. Clin Pharmacol Ther 1994; 55: 661-9
64. Levine MAH, Ogilvie RI, Leenen FHH. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin Pharmacol Ther 1988; 43: 39-48
65. Elliot HL, Meredith PA McNally C, et al. The interactions between nisoldipine and two ß-adrenoceptor antagonists: atenolol and propranolol. Br J Clin Pharmacol 1991; 32: 379-85
66. Meredith PA, Pasanisi F, Elliott HL, et al. The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. Br J Clin Pharmacol 1985; 20: 235-7
67. North of England Stable Angina Guideline Development Group. North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of stable angina. BMJ 1996; 312: 827-32
68. Melcher A, Dens J, Curry P, et al. Nisoldipine CC: clinical experience in ischaemic heart disease. Cardiology 1997; 88 Suppl. 1: 17-23
69. Burris JF, Gilbert JC, Pettis PK, et al. A multicenter, placebo-controlled study of once-daily treatment with nisoldipine coat-core in combination with atenolol in hypertension [abstract]. Am J Hypertens 1994; 7 Pt 2: 45A
70. Kirch W, Stenzel J, Dylewicz P, et al. Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin. Br J Clin Pharmacol 1986; 22: 155-9
71. Ziepler R, Horstmann R, Wingender W, et al. Do dihydropyridines influence pharmacokinetic and hemodynamic parameters of digoxin [abstract]. J Clin Pharmacol 1987; 27 (9): 712
72. Kuhlmann J, Ziegler R, Wingender W, et al. Beeinflussen Nisoldipin, Nitrendipin und Nimodipin die Pharmakokinetik und Wirksamkeit von Herzglykosiden? [abstract]. Z Kardiol 1986; 75 Suppl. 4: 78
73. Kirch W, Dylewicz P, Ohnhaus EE. Interaction of nisoldipine. a new calcium channel blocker, with digoxin and digitoxin in patients with cardiac insufficiency. A placebo-controlled donble blind study [abstract]. Naunyn-Schmiedebergs Arch Pharmacol 1985; 329 Suppl.: R97
74. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-5
75. Bailey DG, Bend JR, Arnold JMO, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60 (1): 25-33